Charles J. Ferro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7457387/publications.pdf

Version: 2024-02-01

216	6,831	57758	79698
papers	citations	44 h-index	73 g-index

230	230	230	8757
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chronic Kidney Disease and CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2019, 74, 1823-1838.	2.8	403
2	Systemic Endothelin Receptor Blockade Decreases Peripheral Vascular Resistance and Blood Pressure in Humans. Circulation, 1996, 93, 1860-1870.	1.6	257
3	Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease. Journal of the American College of Cardiology, 2009, 54, 505-512.	2.8	256
4	Inhibition of Neutral Endopeptidase Causes Vasoconstriction of Human Resistance Vessels In Vivo. Circulation, 1998, 97, 2323-2330.	1.6	158
5	A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project. Palliative Medicine, 2011, 25, 525-552.	3.1	153
6	Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 727-749.	9.6	153
7	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, 2019, 34, 208-230.	0.7	147
8	Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study. American Journal of Kidney Diseases, 2010, 56, 1082-1094.	1.9	144
9	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace, 2015, 17, 1169-1196.	1.7	138
10	Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology, 2016, 17, 127.	1.8	134
11	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Associationâ€“European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. Nephrology Dialysis Transplantation, 2017, 32, 620-640.	0.7	133
12	Arterial stiffness in chronic kidney disease: causes and consequences. Heart, 2010, 96, 817-823.	2.9	124
13	Arterial disease in chronic kidney disease. Heart, 2013, 99, 365-372.	2.9	119
14	Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibodyâ€“associated vasculitides: A matchedâ€pair cohort study. Arthritis and Rheumatism, 2009, 60, 3493-3500.	6.7	110
15	Association between periodontitis and mortality in stages 3â€“5 chronic kidney disease: <scp>NHANES III</scp> and linked mortality study. Journal of Clinical Periodontology, 2016, 43, 104-113.	4.9	110
16	Cardiovascular Effects of Sevelamer in Stage 3 CKD. Journal of the American Society of Nephrology: JASN, 2013, 24, 842-852.	6.1	108
17	Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: Cause or association?. Atherosclerosis, 2012, 223, 86-94.	0.8	107
18	Defining the Natural History of Uremic Cardiomyopathy in Chronic Kidney Disease. JACC: Cardiovascular Imaging, 2014, 7, 703-714.	5.3	92

#	Article	IF	Citations
19	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nature Reviews Nephrology, 2018, 14, 337-351.	9.6	89
20	Comparison of magnetic resonance feature tracking for systolic and diastolic strain and strain rate calculation with spatial modulation of magnetization imaging analysis. Journal of Magnetic Resonance Imaging, 2015, 41, 1000-1012.	3.4	87
21	Diffuse Interstitial Fibrosis and Myocardial Dysfunction in Early Chronic Kidney Disease. American Journal of Cardiology, 2015, 115, 1311-1317.	1.6	87
22	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors. Hypertension, 2016, 67, 368-377.	2.7	85
23	Subclinical Abnormalities of Left Ventricular Myocardial Deformation in Early-Stage Chronic Kidney Disease: The Precursor of Uremic Cardiomyopathy?. Journal of the American Society of Echocardiography, 2008, 21, 1293-1298.	2.8	84
24	Impact of renal function on survival after transcatheter aortic valve implantation (TAVI): an analysis of the UK TAVI registry. Heart, 2015, 101, 546-552.	2.9	84
25	The impact of arteriovenous fistula formation on central hemodynamic pressures in chronic renal failure patients: A prospective study. American Journal of Kidney Diseases, 2002, 40, 753-759.	1.9	82
26	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 836-849.	5.2	80
27	Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart, 2008, 94, 1038-1043.	2.9	79
28	The Clinical Potential of Endothelin Receptor Antagonists in Cardiovascular Medicine. Drugs, 1996, 51, 12-27.	10.9	70
29	Atrial Fibrillation in CKD: Balancing the Risks and Benefits of Anticoagulation. American Journal of Kidney Diseases, 2013, 62, 615-632.	1.9	69
30	Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 2576-2582.	0.7	64
31	Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart, 2012, 98, 219-224.	2.9	64
32	The increase in human plasma immunoreactive endothelin but not big endothelinâ€1 or its Câ€terminal fragment induced by systemic administration of the endothelin antagonist TAKâ€044. British Journal of Pharmacology, 1996, 119, 311-314.	5.4	62
33	Central aortic pressure augmentation in stable renal transplant recipients. Kidney International, 2002, 62, 166-171.	5.2	61
34	Reproducibility of derived central arterial waveforms in patients with chronic renal failure. Clinical Science, 2002, 103, 59-65.	4.3	60
35	Endothelial Dysfunction and Hypertension. Drugs, 1997, 53, 30-41.	10.9	57
36	Association between Younger Age When First Overweight and Increased Risk for CKD. Journal of the American Society of Nephrology: JASN, 2013, 24, 813-821.	6.1	56

#	Article	IF	Citations
37	Hypertension in dialysis patients. Journal of Hypertension, 2017, 35, 657-676.	0.5	56
38	Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease. PLoS ONE, 2017, 12, e0175200.	2.5	56
39	Effect of Spironolactone on Left Ventricular Systolic and Diastolic Function in Patients With Early Stage Chronic Kidney Disease. American Journal of Cardiology, 2010, 106, 1505-1511.	1.6	55
40	The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology, 2012, 73, 447-454.	2.4	55
41	Predicting 5-Year Risk of Kidney Transplant Failure: A Prediction Instrument Using Data Available at 1 Year Posttransplantation. American Journal of Kidney Diseases, 2014, 63, 643-651.	1.9	55
42	Low birth weight, later renal function, and the roles of adulthood blood pressure, diabetes, and obesity in a British birth cohort. Kidney International, 2013, 84, 1262-1270.	5.2	53
43	Urinary endotrophin predicts disease progression in patients with chronic kidney disease. Scientific Reports, 2017, 7, 17328.	3.3	52
44	Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-SchÃ¶nlein purpura): a retrospective cohort study using routinely collected primary care data. Annals of the Rheumatic Diseases, 2019, 78, 261-269.	0.9	50
45	Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 22, 3228-3234.	0.7	47
46	Volume overload in hemodialysis: diagnosis, cardiovascular consequences, and management. Nephrology Dialysis Transplantation, 2021, 36, 2182-2193.	0.7	45
47	Early-Life Overweight Trajectory and CKD in the 1946 British Birth Cohort Study. American Journal of Kidney Diseases, 2013, 62, 276-284.	1.9	44
48	Cross-Sectional Analysis of Abnormalities of Mineral Homeostasis, Vitamin D and Parathyroid Hormone in a Cohort of Pre-Dialysis Patients. Nephron Clinical Practice, 2007, 107, c109-c116.	2.3	42
49	Health-Related Quality of Life Impacts Mortality but Not Progression to End-Stage Renal Disease in Pre-Dialysis Chronic Kidney Disease: A Prospective Observational Study. PLoS ONE, 2016, 11, e0165675.	2.5	41
50	Endothelin receptor antagonism in patients with chronic heart failure. Cardiovascular Research, 2000, 47, 166-172.	3.8	38
51	The natural history of, and risk factors for, progressive Chronic Kidney Disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. BMC Nephrology, 2013, 14, 95.	1.8	37
52	Serum Polyclonal Immunoglobulin Free Light Chain Levels Predict Mortality in People With Chronic Kidney Disease. Mayo Clinic Proceedings, 2014, 89, 615-622.	3.0	37
53	Coronary Artery Calcium Assessment in CKD: Utility in Cardiovascular Disease Risk Assessment and Treatment?. American Journal of Kidney Diseases, 2015, 65, 937-948.	1.9	37
54	Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. British Journal of Clinical Pharmacology, 1999, 48, 336-344.	2.4	36

#	Article	IF	Citations
55	Incidence and impact on outcomes of acute kidney injury after a stroke: a systematic review and meta-analysis. BMC Nephrology, 2018, 19, 283.	1.8	36
56	Reproducibility of derived central arterial waveforms in patients with chronic renal failure. Clinical Science, 2002, 103, 59.	4.3	34
57	The treatment of coronary artery disease in patients with chronic kidney disease. QJM - Monthly Journal of the Association of Physicians, 2006, 99, 723-736.	0.5	34
58	Oxidative stress links periodontal inflammation and renal function. Journal of Clinical Periodontology, 2021, 48, 357-367.	4.9	34
59	Cytomegalovirus Seropositivity Is Associated with Increased Arterial Stiffness in Patients with Chronic Kidney Disease. PLoS ONE, 2013, 8, e55686.	2.5	33
60	Cytomegalovirus infection is associated with an increase in systolic blood pressure in older individuals. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 595-600.	0.5	32
61	Dialysis Following Transcatheter AorticÂValve Replacement: RiskÂFactorsÂandÂOutcomes. JACC: Cardiovascular Interventions, 2017, 10, 2040-2047.	2.9	31
62	Fracture risk and mortality postâ€kidney transplantation. Clinical Transplantation, 2015, 29, 1004-1012.	1.6	30
63	Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trialâ€"a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25Âmg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials, 2014, 15, 160.	1.6	29
64	Variability in cardiac MR measurement of left ventricular ejection fraction, volumes and mass in healthy adults: defining a significant change at 1 year. British Journal of Radiology, 2015, 88, 20140831.	2.2	29
65	Associations of Blood Pressure With Geographical Latitude, Solar Radiation, and Ambient Temperature: Results From the Chilean Health Survey, 2009â€"2010: TableÂ1.. American Journal of Epidemiology, 2016, 183, 1071-1073.	3.4	29
66	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. Europace, 2020, 22, 496-505.	1.7	29
67	Serum phosphate and calcium concentrations are associated with reduced patient survival following kidney transplantation. Clinical Transplantation, 2011, 25, 406-416.	1.6	27
68	Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?. Pediatric Nephrology, 2020, 35, 937-957.	1.7	27
69	Defining Myocardial Abnormalities Across the Stages of Chronic Kidney Disease. JACC: Cardiovascular Imaging, 2020, 13, 2357-2367.	5.3	27
70	The relationship between highâ€sensitivity <scp>CRP</scp> and polyclonal Free Light Chains as markers of inflammation in chronic disease. International Journal of Laboratory Hematology, 2014, 36, 415-424.	1.3	26
71	Diffuse Myocardial Interstitial Fibrosis and Dysfunction in Early Chronic Kidney Disease. American Journal of Cardiology, 2018, 121, 656-660.	1.6	26
72	Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Journal of Infectious Diseases, 2019, 219, 234-244.	4.0	26

#	Article	IF	Citations
73	Allopurinol Is an Independent Determinant of Improved Arterial Stiffness in Chronic Kidney Disease: A Cross-Sectional Study. PLoS ONE, 2014, 9, e91961.	2.5	26
74	Myocardial disease in systemic vasculitis and autoimmune disease detected by cardiovascular magnetic resonance. Rheumatology, 2007, 46, 1208-1209.	1.9	25
75	Glucocorticoid activation by 11Î²â€hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A crossâ€sectional study. Clinical Endocrinology, 2019, 90, 241-249.	2.4	25
76	The periodontal health component of the Renal Impairment In Secondary Care (RIISC) cohort study: a description of the rationale, methodology and initial baseline results. Journal of Clinical Periodontology, 2014, 41, 653-661.	4.9	24
77	Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy?. Heart, 2019, 105, 1302-1309.	2.9	24
78	Acute kidney injury is more common in men than women after accounting for socioeconomic status, ethnicity, alcohol intake and smoking history. Biology of Sex Differences, 2021, 12, 30.	4.1	24
79	Is lowering phosphate exposure the key to preventing arterial stiffening with age?. Heart, 2009, 95, 1770-1772.	2.9	23
80	Modulation of stroke risk in chronic kidney disease. CKJ: Clinical Kidney Journal, 2016, 9, 29-38.	2.9	23
81	Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaudâ€™s disease. British Journal of Clinical Pharmacology, 1999, 47, 507-513.	2.4	22
82	Sodium–glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. Journal of Hypertension, 2021, 39, 1090-1097.	0.5	22
83	Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies. Drugs, 2021, 81, 1467-1489.	10.9	22
84	Outcomes After Weekend Admission for Deceased Donor Kidney Transplantation. Transplantation, 2017, 101, 2244-2252.	1.0	21
85	Hospital acquired Acute Kidney Injury is associated with increased mortality but not increased readmission rates in a UK acute hospital. BMC Nephrology, 2017, 18, 317.	1.8	21
86	Early effects of kidney transplantation on the heart - A cardiac magnetic resonance multi-parametric study. International Journal of Cardiology, 2019, 293, 272-277.	1.7	21
87	Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU. BMC Nephrology, 2013, 14, 218.	1.8	20
88	Serum tryptase concentration and progression to endâ€stage renal disease. European Journal of Clinical Investigation, 2016, 46, 460-474.	3.4	20
89	The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis. Arthritis Research and Therapy, 2018, 20, 194.	3.5	20
90	Clinical Potential of Targeting Fibroblast Growth Factorâ€23 and Î±Klotho in the Treatment of Uremic Cardiomyopathy. Journal of the American Heart Association, 2020, 9, e016041.	3.7	20

#	Article	IF	Citations
91	The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology, 2010, 73, 566-572.	2.4	19
92	Understanding the effects of chronic kidney disease on cardiovascular risk: are there lessons to be learnt from healthy kidney donors?. Journal of Human Hypertension, 2012, 26, 141-148.	2.2	18
93	Cognitive and Kidney Function: Results from a British Birth Cohort Reaching Retirement Age. PLoS ONE, 2014, 9, e86743.	2.5	18
94	Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients. CKJ: Clinical Kidney Journal, 2021, 14, 593-601.	2.9	18
95	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrology Dialysis Transplantation, 2021, 36, 1326-1346.	0.7	18
96	Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study. Hypertension Research, 2011, 34, 113-119.	2.7	17
97	Effects of age and chronic kidney disease on regional aortic distensibility: A cardiovascular magnetic resonance study. International Journal of Cardiology, 2013, 168, 4249-4254.	1.7	17
98	Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 599-613.	1.7	17
99	Prognostic Utility of Calcium Scoring as an Adjunct to Stress Myocardial Perfusion Scintigraphy in End-Stage Renal Disease. American Journal of Cardiology, 2016, 117, 1387-1396.	1.6	17
100	Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial. BMJ Open, 2016, 6, e010519.	1.9	16
101	Frailty Intervention Trial iN End-Stage patientS on haemodialysis (FITNESS): study protocol for a randomised controlled trial. Trials, 2018, 19, 457.	1.6	16
102	Hypertension in kidney transplantation: a consensus statement of the â€˜hypertension and the kidneyâ€™ working group of the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1513-1521.	0.5	16
103	Bosentan in Essential Hypertension. New England Journal of Medicine, 1998, 339, 346-347.	27.0	15
104	Republished paper: Arterial stiffness in chronic kidney disease: causes and consequences. Postgraduate Medical Journal, 2010, 86, 560-566.	1.8	15
105	Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: Rationale and design of the EARNEST study. American Heart Journal, 2014, 167, 141-149.e2.	2.7	15
106	Risk of post-transplantation diabetes mellitus is greater in South Asian versus Caucasian kidney allograft recipients. Transplant International, 2016, 29, 727-739.	1.6	15
107	A novel biomarker of laminin turnover is associated with disease progression and mortality in chronic kidney disease. PLoS ONE, 2018, 13, e0204239.	2.5	15
108	Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 1872-1881.	0.7	15

#	Article	IF	Citations
109	Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study. Journal of Hypertension, 2020, 38, 1849-1856.	0.5	15
110	Correlations, agreement and utility of frailty instruments in prevalent haemodialysis patients: baseline cohort data from the FITNESS study. CKJ: Clinical Kidney Journal, 2022, 15, 145-152.	2.9	15
111	Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphism and Left Ventricular Function in Early Chronic Kidney Disease. PLoS ONE, 2015, 10, e0116160.	2.5	15
112	Vitamin B12 deficiency is associated with geographical latitude and solar radiation in the older population. Journal of Photochemistry and Photobiology B: Biology, 2014, 140, 8-13.	3.8	14
113	Relevance of physicochemical properties and functional pharmacology data to predict the clinical safety profile of direct oral anticoagulants. Pharmacology Research and Perspectives, 2020, 8, e00603.	2.4	14
114	Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. Journal of Human Hypertension, 2021, 35, 499-509.	2.2	14
115	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 31-42.	2.9	14
116	Forearm vasoconstriction to endothelin-1 is impaired, but constriction to sarafotoxin 6c and vasodilatation to BQ-123 unaltered, in patients with essential hypertension. Clinical Science, 2002, 103, 53S-58S.	4.3	13
117	Chronic kidney disease as a cardiovascular risk factor: lessons from kidney donors. Journal of the American Society of Hypertension, 2018, 12, 497-505.e4.	2.3	13
118	Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial. Trials, 2016, 17, 338.	1.6	12
119	SGLT-2 Inhibitors to Treat Hyponatremia Associated with SIADH: A Novel Indication?. American Journal of Nephrology, 2020, 51, 553-555.	3.1	12
120	Intravenous iron therapy and the cardiovascular system: risks and benefits. CKJ: Clinical Kidney Journal, 2021, 14, 1067-1076.	2.9	12
121	Blood pressure targets in CKD 2021: the never-ending guidelines debacle. CKJ: Clinical Kidney Journal, 2022, 15, 845-851.	2.9	12
122	Management of pain in chronic kidney disease. Progress in Palliative Care, 2009, 17, 186-195.	1.2	11
123	Arterial stiffness in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2019, 28, 527-536.	2.0	11
124	Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study. PLoS Medicine, 2021, 18, e1003405.	8.4	11
125	Changes in left ventricular structure and function associated with renal transplantation: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 2045-2057.	3.1	11
126	The Role of Uric Acid in the Acute Myocardial Infarction: A Narrative Review. Angiology, 2022, 73, 9-17.	1.8	11

#	Article	IF	Citations
127	Serum Phosphate Measured at 6 and 12 Months After Successful Kidney Transplant Is Independently Associated With Subsequent Graft Loss. Experimental and Clinical Transplantation, 2012, 10, 119-124.	0.5	11
128	Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. Trials, 2011, 12, 30.	1.6	10
129	Aortic Calcification and Femoral Bone Density Are Independently Associated with Left Ventricular Mass in Patients with Chronic Kidney Disease. PLoS ONE, 2012, 7, e39241.	2.5	10
130	Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1140-1144.	0.7	10
131	A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial. American Heart Journal, 2017, 191, 37-46.	2.7	10
132	Role of hypertension in kidney transplant recipients. Journal of Human Hypertension, 2021, 35, 958-969.	2.2	10
133	Reninâ€“angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 397-406.	2.9	10
134	Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial. Trials, 2014, 15, 158.	1.6	9
135	Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease?. Current Opinion in Nephrology and Hypertension, 2018, 27, 420-425.	2.0	9
136	Changes in Blood Pressure and Arterial Hemodynamics following Living Kidney Donation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1330-1339.	4.5	9
137	Management of pain in renal failure. , 2010, , 139-188.		9
138	Spironolactone increases serum uric acid levels in patients with chronic kidney disease. Journal of Human Hypertension, 2014, 28, 210-211.	2.2	8
139	Bayesian Analysis of Glomerular Filtration Rate Trajectories in Kidney Transplant Recipients. Transplantation, 2015, 99, 533-539.	1.0	8
140	Arterial stiffness alone does not explain arteriovenous fistula outcomes. Journal of Vascular Access, 2018, 19, 63-68.	0.9	8
141	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine, 2020, 382, e65.	27.0	8
142	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors at 5 Years. Hypertension, 2021, 77, 1273-1284.	2.7	8
143	Randomised-controlled trials in chronic kidney disease - a call to arms!. International Journal of Clinical Practice, 2012, 66, 913-915.	1.7	7
144	Hypertension, arterial haemodynamics and left ventricular disease: historical observations. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 709-716.	0.5	7

#	Article	IF	Citations
145	Skewing of Female X-Chromosome Inactivation. Transplantation, 2013, 95, e25-e28.	1.0	7
146	Phosphate: are we squandering a scarce commodity?. Nephrology Dialysis Transplantation, 2015, 30, 163-168.	0.7	7
147	INfluence of Successful Periodontal Intervention in REnal Disease (INSPIRED): study protocol for a randomised controlled pilot clinical trial. Trials, 2017, 18, 535.	1.6	7
148	Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies. Nephrology Dialysis Transplantation, 2021, 36, 1386-1388.	0.7	7
149	Myocardial characterization in pre-dialysis chronic kidney disease: a study of prevalence, patterns and outcomes. BMC Cardiovascular Disorders, 2019, 19, 295.	1.7	7
150	Accuracy of Peridialytic, Intradialytic, and Scheduled Interdialytic Recordings in Detecting Elevated Ambulatory Blood Pressure in Hemodialysis Patients. American Journal of Kidney Diseases, 2021, 78, 630-639.e1.	1.9	7
151	Sex differences in ambulatory blood pressure levels, control, and phenotypes of hypertension in kidney transplant recipients. Journal of Hypertension, 2022, 40, 356-363.	0.5	7
152	Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease. PLoS ONE, 2018, 13, e0197043.	2.5	6
153	Is blood pressure measured correctly in dialysis centres? Physicians' and patients' views. Nephrology Dialysis Transplantation, 2019, 34, 1612-1615.	0.7	6
154	Acute kidney injury calculated using admission serum creatinine underestimates 30-day and 1-year mortality after acute stroke. CKJ: Clinical Kidney Journal, 2020, 13, 46-54.	2.9	6
155	Coronary flow velocity reserve and inflammatory markers in living kidney donors. International Journal of Cardiology, 2020, 320, 141-147.	1.7	6
156	Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, CJN.01930221.	4.5	6
157	Functional Studies in Small Arteries Do Not Support a Primary Role for Endothelin in the Pathogenesis of Raynaud's Disease. Journal of Cardiovascular Pharmacology, 1998, 31, S473-S476.	1.9	6
158	Anticoagulant strategies for the patient with chronic kidney disease. Clinical Medicine, 2020, 20, 151-155.	1.9	6
159	Central pulse pressure in patients with chronic kidney disease and in renal transplant recipients. Journal of Human Hypertension, 2014, 28, 180-185.	2.2	5
160	Renal function and the longâ€term clinical outcomes of cardiac resynchronization therapy with or without defibrillation. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 595-602.	1.2	5
161	Polypharmacology of clinical sodium glucose coâ€transport protein 2 inhibitors and relationship to suspected adverse drug reactions. Pharmacology Research and Perspectives, 2021, 9, e00867.	2.4	5
162	Premature coronary artery disease and early stage chronic kidney disease. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 683-686.	0.5	4

#	Article	IF	Citations
163	Results of Serial Myocardial Perfusion Imaging in End-Stage Renal Disease. American Journal of Cardiology, 2018, 121, 661-667.	1.6	4
164	Humoral immunity to memory antigens and pathogens is maintained in patients with chronic kidney disease. PLoS ONE, 2018, 13, e0195730.	2.5	4
165	Cytomegalovirus seropositivity is independently associated with cardiovascular disease in non-dialysis dependent chronic kidney disease. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 253-257.	0.5	4
166	Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: AÂcohort study. PLoS Medicine, 2020, 17, e1003050.	8.4	4
167	The effect of admission and pre-admission serum creatinine as baseline to assess incidence and outcomes of acute kidney injury in acute medical admissions. Nephrology Dialysis Transplantation, 2021, , .	0.7	4
168	Early renal function trajectories, cytomegalovirus serostatus and long-term graft outcomes in kidney transplant recipients. BMC Nephrology, 2021, 22, 102.	1.8	4
169	Ambulatory blood pressure changes with lung ultrasound-guided dry-weight reduction in hypertensive hemodialysis patients: 12-month results of a randomized controlled trial. Journal of Hypertension, 2021, 39, 1444-1452.	0.5	4
170	The burden of subclinical cardiovascular disease in children and young adults with chronic kidney disease and on dialysis. CKJ: Clinical Kidney Journal, 2022, 15, 287-294.	2.9	4
171	Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function. CardioRenal Medicine, 2020, 10, 440-451.	1.9	4
172	THE IMPORTANCE OF RENINâ€ANGIOTENSIN BLOCKADE IN PATIENTS WITH CARDIOâ€RENAL DISEASE. Journal of Renal Care, 2010, 36, 97-105.	1.2	3
173	Impaired circumferential and longitudinal myocardial deformation in early stage chronic kidney disease: the earliest features of uremic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2013, 15, .	3.3	3
174	Acute Care QUAliTy in chronic Kidney disease (ACQUATIK): a prospective cohort study exploring outcomes of patients with chronic kidney disease. BMJ Open, 2015, 5, e006987-e006987.	1.9	3
175	Coronary microvascular dysfunction is associated with degree of anaemia in endâ€stage renal disease. BMC Cardiovascular Disorders, 2021, 21, 211.	1.7	3
176	Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?. CKJ: Clinical Kidney Journal, 2021, 14, 2472-2482.	2.9	3
177	Fractures in Kidney Transplant Recipients: A Comparative Study Between England and New York State. Experimental and Clinical Transplantation, 2018, 16, 410-418.	0.5	3
178	Risk for subsequent hypertension and cardiovascular disease after living kidney donation: is it clinically relevant?. CKJ: Clinical Kidney Journal, 2022, 15, 644-656.	2.9	3
179	Reduction of blood pressure already in the normal range further regresses left ventricular mass. Heart, 2010, 96, 1080-1080.	2.9	2
180	Invite all donors to participate in follow-up studies. BMJ, The, 2012, 344, e2724-e2724.	6.0	2

#	Article	IF	Citations
181	FO082PROGRESSION OF MYOCARADIAL FIBROSIS IN CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	2
182	Endâ€stage kidney disease patients from ethnic minorities and mortality in coronavirus disease 2019. Hemodialysis International, 2022, 26, 83-93.	0.9	2
183	Renal artery stenting in the correct patients with atherosclerotic renovascular disease: time for a proper renal and cardiovascular outcome study?. CKJ: Clinical Kidney Journal, 0, , .	2.9	2
184	Big endothelin-3 constricts forearm resistance vessels but not hand veins in humans. Clinical Pharmacology and Therapeutics, 2000, 68, 67-74.	4.7	1
185	An increased risk of ischemic heart disease in Wegener's granulomatosis: Comment on the article by Faurschou et al. Arthritis and Rheumatism, 2010, 62, 637-638.	6.7	1
186	Unexpected benefits of participation in a clinical trial: abdominal aortic aneurysms in patients with chronic kidney disease. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 1213-1216.	0.5	1
187	SPRINTing towards trials of blood pressure reduction to reduce CKD progression?. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 229-230.	4.0	1
188	10â€…Cardiac alterations after renal transplant; contoversies unravelled by cardiac mri. Heart, 2017, 103, A6-A7.	2.9	1
189	11â€…Cpex testing detects subclinical cardiac limitation to exercise in early stage ckd. Heart, 2017, 103, A7.1-A7.	2.9	1
190	CKD Associated Cardiomyopathy: Molecular Mechanisms, Imaging Modalities, Disease Evolution and Interventions. , 2017, , 45-58.		1
191	Hypertension Management in Patients With Autosomal Dominant Polycystic Kidney Disease: Time for a Paradigm Shift?. American Journal of Kidney Diseases, 2020, 76, 743.	1.9	1
192	Is Our Increasing Understanding of PCSK9 and Lp(a) Metabolism the Key to Unlocking the Paradox of Statins Ineffectiveness in Reducing Cardiovascular Events in Advanced CKD?. SN Comprehensive Clinical Medicine, 2022, 4, .	0.6	1
193	The EARNEST Study: Interarm blood pressure differences should also be recorded. American Heart Journal, 2014, 168, e9.	2.7	0
194	Letter by Edwards et al Regarding Article, â€œCoronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fractionâ€• Circulation, 2015, 132, e204.	1.6	0
195	37â€…Cardiovascular Effects of Unilateral Nephrectomy in Human Kidney Donors. Heart, 2015, 101, A20.2-A21.	2.9	0
196	SP028CAVEOLIN-1 POLYMORPHISM ASSOCIATION WITH ARTERIAL STIFFNESS IN NON-DIALYSIS CKD. Nephrology Dialysis Transplantation, 2015, 30, iii389-iii390.	0.7	0
197	MP728SOCIOECONOMIC DEPRIVATION AND OUTCOMES AFTER KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2016, 31, i581-i581.	0.7	0
198	Re: assessment of myocardial fibrosis with T1 mapping MRI. Clinical Radiology, 2016, 71, 1309-1310.	1.1	0

#	Article	IF	Citations
199	The Nephroprotective Effect of Folic Acidâ€"Only a Matter of Homocysteine?. JAMA Internal Medicine, 2017, 177, 286.	5.1	0
200	Definitions of Resistant Hypertension and Epidemiology of Resistant Hypertension. , 2017, , 1-12.		0
201	MP387CARDIAC LIMITATION OCCURS EARLY IN CKD, AND CANNOT BE FULLY EXPLAINED BY ISCHAEMIA OR REDUCED LV COMPLIANCE AS MEASURED BY DIASTOLIC FUNCTION DURING EXERCISE. Nephrology Dialysis Transplantation, 2017, 32, iii570-iii570.	0.7	0
202	MP392CARDIOPULMONARY EXERCISE TESTING DETECTS SUBCLINICAL CARDIAC LIMITATION TO EXERCISE IN EARLY STAGE CKD. Nephrology Dialysis Transplantation, 2017, 32, iii572-iii572.	0.7	0
203	24â€...Myocardial tissue characterisation in progressive CKD: is diffuse interstitial fibrosis the key intermediary of uraemic cardiomyopathy?. , 2018, , .		0
204	Vive les Differences!â€"A case for optimism in the treatment of patients with heart failure and preserved ejection fraction?. International Journal of Clinical Practice, 2019, 73, e13307.	1.7	0
205	P1623MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) AFTER KIDNEY TRANSPLANTATION: A POPULATION-COHORT ANALYSIS OF ENGLISH TRANSPLANT CENTRES. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
206	P0254MYOCARDIAL TISSUE CHARACTERIZATION IN LIVING KIDNEY DONORS 5 YEARS AFTER NEPHRECTOMY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
207	MO108ACCURACY OF PERIDIALYTIC, INTRADIALYTIC AND SCHEDULED INTERDIALYTIC RECORDINGS FOR DIAGNOSING HIGH AMBULATORY BLOOD PRESSURE IN HEMODIALYSIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
208	159â€...Myocardial fibrosis is associated with reduced coronary flow velocity reserve in end-stage renal disease. , 2021, , .		0
209	52â€...Patterns of late gadolinium enhancement in chronic kidney disease: a predictor of clinical outcome data?. , 2018, , .		0
210	Reply. Journal of Hypertension, 2022, 40, 624-626.	0.5	0
211	Trimming the fat: is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review. CKJ: Clinical Kidney Journal, 0, , .	2.9	0
212	Title is missing!. , 2020, 17, e1003050.		0
213	Title is missing!. , 2020, 17, e1003050.		0
214	Title is missing!. , 2020, 17, e1003050.		0
215	Title is missing!. , 2020, 17, e1003050.		0
216	Title is missing!. , 2020, 17, e1003050.		0